Wechat logo 50 41 d4bae92fc2b9067675bfee08d2b00834882415940f50456376420c2e77a679ac
返回

Januvia

Januvia
西他列汀(治疗控制不佳的2型糖尿病)

Definitions

JanuviaPharmacologic class: Dipeptidyl peptidase 4 (DPP-4) inhibitorTherapeutic class: HypoglycemicPregnancy risk category BActionInhibits DPP-4 and slows inactivation of incretin hormones, helping to regulate glucose homeostasis through increased insulin release and decreased glucagon levelsAvailabilityTablets: 25 mg, 50 mg, 100 mg⊘Indications and dosages➣ Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitusAdults: 100 mg P.O. once dailyDosage adjustment• Moderate to severe renal insufficiency or end-stage renal diseaseContraindications• History of serious hypersensitivity to drug (such as anaphylaxis or angioedema)PrecautionsUse cautiously in:• concurrent administration of drugs that cause hypoglycemia (such as sulfonylureas or insulin)• renal impairment, history of pancreatitispregnant or breastfeeding patients• children younger than age 18 (safety and efficacy not established).Administration• Assess renal function before starting therapy.☞ Before starting drug, ask patient about possible risk factors for pancreatitis, such as history of pancreatitis, alcoholism, gallstones, or hypertriglyceridemia. However, it's unknown if these conditions make it more likely that pancreatitis will occur.• Give with or without food.• Be aware that drug shouldn't be used to treat type 1 diabetes mellitus or diabetic ketoacidosis.• Know that when drug is used with a sulfonylurea, a lower dose of sulfonylurea may be required, to reduce risk of hypoglycemia.Adverse reactionsCNS: headacheEENT: nasopharyngitisGI: abdominal pain, nausea, vomiting, diarrhea, pancreatitisGU: acute renal failureRespiratory: upper respiratory tract infectionOther: hypersensitivity reactions (including anaphylaxis, angioedema, exfoliative skin conditions such as Stevens-Johnson syndrome)InteractionsDrug-drug.Digoxin: minimally increased digoxin effect and blood levelInsulin, sulfonylureas: possible increased hypoglycemia riskPatient monitoringMonitor renal function periodically.• Measure patient's weight and body mass index periodically during therapy.• Monitor blood glucose and hemoglobin A1c levels periodically during therapy.☞ Monitor patient for signs and symptoms of hypersensitivity reactions and immediately stop drug and institute emergency measures if such reactions occur.• Check for diabetes signs and symptoms and disease progression routinely during therapy.☞ Be aware of postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue drug.Patient teaching• Instruct patient to take drug with or without food.• Teach patient about signs and symptoms of hypoglycemia (such as blurred vision, confusion, tremor, sweating, excessive hunger, drowsiness, and fast heart rate).☞ Teach patient about signs and symptoms of hypersensitivity reactions (such as rash, throat swelling, or difficulty breathing) and to immediately contact prescriber if these occur.☞ Instruct patient to immediately discontinue drug and report if signs and symptoms of pancreatitis occur (persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting).• Instruct patient to routinely monitor blood glucose levels at home.• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above. JanuviaPharmacologic class: Dipeptidyl peptidase 4 (DPP-4) inhibitorTherapeutic class: HypoglycemicPregnancy risk category B ActionInhibits DPP-4 and slows inactivation of incretin hormones, helping to regulate glucose homeostasis through increased insulin release and decreased glucagon levels AvailabilityTablets: 25 mg, 50 mg, 100 mg ⊘Indications and dosages➣ Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitusAdults: 100 mg P.O. once daily





Sound e31a43d441998f862b764d17930467a5a23de45c433219259bed5eb42e3a7615